Idorsia unveils Sfr575m at-market rights offer

© 2025 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Cookies Settings
Equity
Follow-ons and Rights issues

Idorsia unveils Sfr575m at-market rights offer

Aidan Gregory
October 08, 2020 11:00 am
Idorsia_PA_575_375
Pharmaceuticals being produced at the company STADA Azneimittel AG in Bad Vilbel, Germany, 20 June 2016. STADA specialised on the production of generic medicaments and over-the-counter pharmaceuticals for pharmacies. PHOTO: FRANK RUMPENHORST/dpa | Frank Rumpenhorst/DPA/PA Images

Swiss biotechnology company Idorsia has begun marketing for a Sfr575m at-market rights offer to fund the commercialisation of its lead product candidate.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

SwitzerlandJP MorganCredit SuisseHealth and BiotechEquityEuropeFollow-ons and Rights issuesEMEASRI
AG
Aidan Gregory
Gift this article